logo
Twitter
Discord
Email
logo
agilon health, inc.

agilon health, inc.

NYSE•AGL
CEO: Mr. Steven Jackson Sell
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2021-04-15
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Contact Information
6210 East US Highway 290, Suite 450, Austin, TX, 78723, United States
562-256-3800
www.agilonhealth.com
Market Cap
$297.88M
P/E (TTM)
-1.0
16.5
Dividend Yield
--
52W High
$6.08
52W Low
$0.51
52W Range
4%
Rank60Top 78.6%
2.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q3 2025 Data

Revenue

$1.44B-1.08%
4-Quarter Trend

EPS

-$0.27-8.31%
4-Quarter Trend

FCF

-$21.33M-420.45%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Declines Amid Exits Total revenues $4.363 B, down 4% for nine months ended September 30, 2025, primarily due to membership declines.
Gross Profit Swings Negative Gross profit $69.351 M loss, swinging from $43.1 M profit prior year, reflecting significant operational pressure.
Medical Margin Deterioration Medical margin $17.764 M, sharply declining 91% versus $204.619 M last period, driven by elevated cost trends.
Operating Cash Usage Net cash used in operations $85.226 M for nine months, requiring additional capital resources for future strategic initiatives.

Risk Factors

History of Net Losses History of net losses expected to continue; future expenses projected to increase, pressuring overall financial stability.
Medicare Contract Stability Ability to maintain favorable Medicare Advantage contracts and secure new payor relationships on acceptable terms remains critical.
Medical Cost Overruns Medical expenses incurred on behalf of members may exceed revenues received, negatively impacting operational performance metrics.
Securities Litigation Exposure Facing multiple securities class action lawsuits; ultimate liability or financial impact from early-stage litigation is currently unpredictable.

Outlook

PCP Empowerment Strategy Business model focuses on empowering PCPs through agilon platform, partnership model, and growing network of like-minded physicians.
Payor Data Pipeline Implementation Continuing onboarding payors onto the new Model to gain enhanced visibility into member risk profiles and adjustment factors.
Future Capital Requirements Expecting continued operating losses, potentially requiring additional public or private equity/debt financing to fund growth plans.
Membership Growth Focus Medicare Advantage membership decreased 4%; growth expected in new geographies partially offsetting prior partnership exits.

Peer Comparison

Revenue (TTM)

Community Health Systems, Inc.CYH
$12.64B
+0.7%
Owens & Minor, Inc.OMI
$6.71B
-37.1%
agilon health, inc.AGL
$5.89B
+5.2%

Gross Margin (Latest Quarter)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Definitive Healthcare Corp.DH
76.6%
-1.6pp
Enhabit, Inc.EHAB
46.9%
+0.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EHAB$490.55M-3.7-24.4%43.5%
CYH$448.80M1.3-18.9%84.9%
AURA$414.67M-3.7-64.4%8.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.9%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:-$0.27
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $1.44B-1.1%
    |
    EPS: $-0.27-8.3%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $1.39B-5.9%
    |
    EPS: $-0.25+235.1%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $1.53B-4.5%
    |
    EPS: $0.03+354.5%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $6.06B+40.4%
    |
    EPS: $-0.63+4.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $1.45B+19.4%
    |
    EPS: $-0.29+274.2%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $1.48B+29.0%
    |
    EPS: $-0.07+82.8%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $1.60B+41.2%
    |
    EPS: $0.01-83.0%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 27, 2024|
    Revenue: $4.32B+59.4%
    |
    EPS: $-0.64-146.2%
    Miss